Analyzing R&D Budgets: Grifols, S.A. vs Amicus Therapeutics, Inc.

Biotech R&D: Grifols vs. Amicus - A Decade of Investment

__timestampAmicus Therapeutics, Inc.Grifols, S.A.
Wednesday, January 1, 201447624000180753000
Thursday, January 1, 201576943000224193000
Friday, January 1, 2016104793000197617000
Sunday, January 1, 2017149310000288320000
Monday, January 1, 2018270902000240661000
Tuesday, January 1, 2019286378000276018000
Wednesday, January 1, 2020308443000294216000
Friday, January 1, 2021272049000354881000
Saturday, January 1, 2022276677000361140000
Sunday, January 1, 2023152381000330551000
Loading chart...

Infusing magic into the data realm

A Decade of Innovation: R&D Spending Trends in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Grifols, S.A. and Amicus Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Grifols consistently outspent Amicus, with an average annual R&D budget approximately 41% higher. Notably, Grifols peaked in 2022, investing 3.6 times more than its 2014 expenditure. Meanwhile, Amicus showed a more volatile pattern, with a significant surge in 2018, nearly quadrupling its 2014 budget. However, by 2023, Amicus's R&D spending had decreased by 45% from its 2020 peak. These trends highlight the dynamic nature of R&D investments in the biotech sector, reflecting each company's strategic priorities and market challenges.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025